Zhejiang Jolly Pharmaceutical Co.,LTD Stock

Equities

300181

CNE100001096

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
13.35 CNY -1.11% Intraday chart for Zhejiang Jolly Pharmaceutical Co.,LTD +0.91% +25.23%
Sales 2023 * 1.98B 273M Sales 2024 * - Capitalization 9.36B 1.29B
Net income 2023 * 380M 52.5M Net income 2024 * - EV / Sales 2023 -
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * -
P/E ratio 2023 *
24.7 x
P/E ratio 2024 *
-
Employees 2,455
Yield 2023 *
2.85%
Yield 2024 *
-
Free-Float 42.74%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Jolly Pharmaceutical Co.,LTD(XSEC:300181) added to S&P Global BMI Index CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Announces Cash Dividend on A Shares for the Year 2022, Payable on 30 May 2023 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Approves Cash Dividend for 2022 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Final Cash Dividend for the Year 2022 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Jolly Pharmaceutical Co.,LTD signed an equity transfer agreement to acquire the remaining 48.99% stake in Zhejiang Jolly Baicao Chinese Medicine Decoction Pieces Co., Ltd. from Chen Huan and Chen Zhaorong for RMB 75 million. CI
Zhejiang Jolly Pharmaceutical Co.,LTD Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 31 May 2022 CI
Zhejiang Jolly Pharmaceutical Co.,LTD completed the acquisition of 8% stake in Zhejiang Top Medicine Co.,Ltd. from Yu Yin. CI
Zhejiang Jolly Pharmaceutical Co.,Ltd Approves Cash Dividend for 2021 CI
Zhejiang Jolly Pharmaceutical Co.,LTD Proposes Cash Dividend for 2021 CI
More news
1 day-1.11%
1 week+0.91%
Current month+3.41%
3 months+24.19%
6 months+24.77%
Current year+25.23%
More quotes
1 week
12.71
Extreme 12.71
13.77
1 month
12.23
Extreme 12.23
13.77
Current year
8.36
Extreme 8.36
13.77
1 year
8.36
Extreme 8.36
14.87
3 years
6.83
Extreme 6.83
15.55
5 years
4.64
Extreme 4.64
15.55
10 years
3.33
Extreme 3.33
18.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 18-01-15
Director/Board Member 49 21-01-24
Director/Board Member 44 17-12-31
Members of the board TitleAgeSince
Director/Board Member 49 21-01-24
Chairman 62 03-08-26
Director/Board Member 59 08-01-30
More insiders
Date Price Change Volume
24-04-18 13.35 -1.11% 20,877,120
24-04-17 13.5 +5.14% 18,901,740
24-04-16 12.84 -1.91% 16,275,600
24-04-15 13.09 +1.55% 18,394,450
24-04-12 12.89 -2.57% 20,472,480

End-of-day quote Shenzhen S.E., April 17, 2024

More quotes
Zhejiang Jolly Pharmaceutical Co., Ltd. is a China-based company principally engaged in research, development, manufacture and sales of medicinal fungi series products. The Company’s main business is mainly involved in pharmaceutical manufacturing, among which the activities are involved in manufacture and sale of active pharmaceutical ingredients, tablets, capsules, granules, Lyophilized powders and other products. The main products include Wuling series, bailing tablets series and Chinese medicine drinking tablets series, among others. Through its subsidiaries, the Company is also engaged in pharmaceutical circulation.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300181 Stock